Herbo Drugs & Pharmaceuticals: Cost of Capital and Capital Budgeting Custom Case Solution & Analysis

Evidence Brief: Herbo Drugs and Pharmaceuticals

Financial Metrics

• Risk-Free Rate: 7.14 percent based on the 10-year Indian Government Bond yield (Exhibit 4).
• Market Risk Premium: Estimated at 8.0 percent for the Indian equity market (Exhibit 4).
• Beta (Unlevered): Pharmaceutical industry average is 0.82 (Exhibit 5).
• Cost of Debt: Pre-tax cost of bank loans is 10.5 percent (Paragraph 8).
• Tax Rate: Corporate marginal tax rate is 25.17 percent (Paragraph 8).
• Capital Structure: Current Debt-to-Equity ratio stands at 0.40 (Exhibit 2).
• Project Alpha Investment: 450 million INR (Paragraph 12).
• Project Beta Investment: 600 million INR (Paragraph 14).
• Expected IRR Project Alpha: 16 percent (Exhibit 6).
• Expected IRR Project Beta: 22 percent (Exhibit 6).

Operational Facts

• Project Alpha: Capacity expansion for existing generic drug manufacturing in the domestic market (Paragraph 12).
• Project Beta: Entry into the specialized oncology segment requiring significant research and development (Paragraph 14).
• Market Position: Top 20 pharmaceutical firm in India by revenue (Paragraph 2).
• Geography: Primary operations located in Mumbai and manufacturing units in Gujarat (Paragraph 3).
• Operational Lifecycle: Project Alpha has a 5-year expected life; Project Beta has a 10-year expected life (Exhibit 6).

Stakeholder Positions

• Rajesh Sharma (CFO): Advocates for a single company-wide WACC to maintain consistency in capital allocation (Paragraph 7).
• Dr. Vinay Gupta (CEO): Concerned that a high hurdle rate will stifle the innovation needed for Project Beta (Paragraph 9).
• Board of Directors: Demands a clear justification for the 1050 million INR total capital expenditure (Paragraph 15).

Information Gaps

• Flotation Costs: The case does not specify costs for issuing new equity if internal accruals are insufficient.
• Project-Specific Betas: While industry beta is provided, the specific risk profile of the oncology segment versus generics is not quantified.
• Terminal Value Assumptions: Detailed cash flow projections beyond the initial periods for Project Beta are absent.

Strategic Analysis

Core Strategic Question

Herbo Drugs must determine if it should utilize a uniform Weighted Average Cost of Capital (WACC) or project-specific hurdle rates to evaluate two distinct investments: a low-risk expansion (Alpha) and a high-risk R&D entry (Beta). The decision will dictate the long-term growth trajectory and risk profile of the firm.

Structural Analysis

Strategic Options

Option 1: Apply Uniform WACC (12.2%) to both projects

• Rationale: Simplifies decision-making and prevents internal divisional bias.
• Trade-offs: Risks over-investing in high-risk projects (Beta) and under-investing in low-risk projects (Alpha) if the rate does not reflect specific risk.
• Resource Requirements: 1050 million INR total capital.

Option 2: Risk-Adjusted Hurdle Rates

• Rationale: Assign 10% to Alpha (low risk) and 18% to Beta (high risk).
• Trade-offs: More accurate NPV calculation but requires subjective judgment on risk premiums.
• Resource Requirements: Specialized financial modeling capabilities.

Preliminary Recommendation

Herbo Drugs should adopt Option 2. Using a uniform 12.2 percent WACC underestimates the risk of the oncology segment. Project Alpha (IRR 16%) is a clear value creator. Project Beta (IRR 22%) also exceeds its higher risk-adjusted hurdle rate, suggesting both should be approved. However, the firm must ensure the 22 percent IRR for Beta accounts for the high failure rate of R&D.

Implementation Roadmap

Critical Path

• Month 1: Finalize capital structure targets. Confirm if the 0.40 Debt-to-Equity ratio will be maintained or if new equity issuance is required for the 1050 million INR outlay.
• Month 2: Secure debt financing. Negotiate with lenders to lock in the 10.5 percent pre-tax rate before market fluctuations.
• Month 3: Establish project governance. Create separate oversight committees for Project Alpha (operational efficiency focus) and Project Beta (scientific milestone focus).
• Month 4: Deploy 450 million INR to Project Alpha. Immediate procurement of manufacturing equipment to meet domestic demand.

Key Constraints

• Capital Rationing: If the board limits spending to internal cash flows, Project Beta must be phased or delayed to prioritize the immediate cash-generating Alpha project.
• Regulatory Hurdles: Project Beta (Oncology) requires stringent clinical trial approvals in India, which can extend timelines by 24 to 36 months beyond the initial plan.

Risk-Adjusted Implementation Strategy

The strategy assumes a phased roll-out. Project Alpha will serve as the primary cash generator to fund the ongoing R&D costs of Project Beta. A contingency fund of 15 percent should be added to the Project Beta budget to account for potential clinical trial delays and regulatory cost increases. If Project Alpha does not achieve 80 percent of its revenue targets by year two, the Project Beta spending must be re-evaluated to preserve the balance sheet.

Executive Review and BLUF

BLUF

Herbo Drugs should approve both Project Alpha and Project Beta using project-specific hurdle rates rather than a single WACC. The calculated WACC of 12.2 percent is appropriate for the company as a whole but fails to capture the risk divergence between generic expansion and oncology R&D. Project Alpha offers a safe 16 percent IRR, providing immediate cash flow. Project Beta, while riskier, offers a 22 percent IRR that exceeds even a punitive 18 percent hurdle rate. Executing both requires 1050 million INR, which is achievable by maintaining the current 0.40 debt-to-equity ratio. Delaying Project Beta cedes a high-margin segment to competitors, while skipping Alpha ignores certain 3.8 percent excess returns over the cost of capital.

Dangerous Assumption

The analysis assumes the 22 percent IRR for Project Beta is a probability-weighted figure. In pharmaceutical R&D, the distribution of outcomes is binary. If the 22 percent represents only the success case, the true expected NPV is likely negative when adjusted for the high probability of clinical failure.

Unaddressed Risks

• Interest Rate Risk: The 10.5 percent cost of debt is based on current bank rates. A 200-basis point increase in Indian central bank rates would raise the WACC to nearly 13 percent, narrowing the margin of safety for Project Alpha.
• Talent Scarcity: Entering the oncology segment requires specialized scientific personnel. The cost of hiring this talent is not explicitly detailed in the capital budgeting exhibits and could inflate operational expenses.

Unconsidered Alternative

The team did not consider a joint venture for Project Beta. Partnering with a global pharmaceutical firm for the oncology entry would reduce the 600 million INR capital requirement and transfer significant technical and regulatory risk to a partner with existing segment expertise.

Verdict

APPROVED FOR LEADERSHIP REVIEW